Drug intelligence / Profile preview

SAB-181

Development stage: Unknown
Lead developer: SAB Biotherapeutics
Modality: Antibody-Based Therapeutics
Administration: Intravenous

Overview

SAB-181 is a **polyclonal antibody therapeutic candidate** developed using **transchromosomic bovine technology** by SAB Biotherapeutics[5][7][11]. It is designed to offer targeted, broadly neutralizing antibodies potentially for use in infectious disease or immunological indications. It consists of fully human antibodies produced by genetically engineered cattle that have been immunized with a specific antigen. Development status was recently listed as “pending”, with preclinical/early phase data referenced; detailed mechanism of action and disease indications have not been publicly disclosed[5][7][11].

Brand names: SAB-181SAB181SAB 181
Other names: SAB-181SAB181SAB 181

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on SAB-181.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAB-181.

Explore the full profile